Track topics on Twitter Track topics that are important to you
LONDON (Reuters) - Scientists have developed a new three-in-one blood test that has the potential to turn AstraZeneca's drug Lynparza into a precision medicine for prostate cancer.
Original Article: New test may turn AZ's Lynparza into precision drug for prostate cancerNEXT ARTICLE
AstraZeneca is ranked 6th in the world, based on a pharmaceutical annual sales, which were valued at $32,800 million in 2009. it is a global company, working in more than 100 countries, and employing 62,000 people, around a sixth of which are dedic...
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...
Prostate cancer (cancer de prostata) Prostate cancer (cancer de prostata) is a form of cancer that develops in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, there are cases of aggressive prostat...